回复：

性别对阿贝西利的暴露没有影响。

详细信息

根据癌症患者的人群药代动力学分析，性别（135 名男性和 859 名女性）对 阿贝西利 的暴露没有影响。¹

其他出版物进一步支持阿贝西利暴露不受性别影响。^2-4

上次审阅日期：2024年10月3日

参考文献

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. Tate SC, Sykes AK, Kulanthaivel P, et al. A population pharmacokinetic and pharmacodynamic analysis of abemaciclib in a phase I clinical trial in cancer patients. Clin Pharmacokinet. 2018;57(3):335-344. http://dx.doi.org/10.1007/s40262-017-0559-8

3. Chigutsa E, Kambhampati SRP, Sykes AK, et al. Development and application of a mechanistic population modeling approach to describe abemaciclib pharmacokinetics. CPT Pharmacometrics Syst Pharmacol. 2020;9(9):523-533. https://doi.org/10.1002/psp4.12544

4. Groenland SL, Martínez-Chávez A, van Dongen MGJ, et al. Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib. Clin Pharmacokinet. 2020;59 (12):1501-1520. https://doi.org/10.1007/s40262-020-00930-x